AVITA Medical, Inc.
RCELHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. With a market capitalization of $479.7M, it sits in small-cap territory. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Market Cap
$479.7M
Beta
1.99
P/E (TTM)
—
P/E (Fwd)
-36.59
EPS (TTM)
$-1.43
EPS (Fwd)
$-0.42
ROE
—
ROA
-41.6%
Cash
$11.1M
Total Debt
$48.5M
Free CF
-$13.3M
52W Change
290.7%
Annual Financials
Cash vs Debt
Where RCEL stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, RCEL finished 99.69% above its 150-day moving average ($6.53) and 118.79% above its 200-day moving average ($5.96). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RCEL overbought or oversold?
At the October 19, 2026 close, RCEL's RSI(14) was 67.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, RCEL has $11.1M in cash with $48.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$13.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $34.4M (2022) to $71.6M (2025), reflecting a 108% increase over the period.
AVITA Medical, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RCEL.